News

PRAC February 2024: reminder of serious adverse reactions when Paxlovid is taken in combination with certain immunosuppressants

During its February 2024 meeting, the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency reminded healthcare professionals of the risk of serious and potentially fatal adverse reactions with Paxlovid when used in combination with certain immunosuppressants.

Give your opinion on a genetically modified medicine for the treatment of limb girdle muscular dystrophy

The FPS Public Health and the FAMHP invite you to participate in the public consultation on a clinical trial of the genetically modified medicine SRP-9003 for the treatment of limb girdle muscular dystrophy. The public consultation runs from 14 February 2024 to 14 March 2024.

The FAMHP is ready for the Belgian presidency of the Council of the European Union

From 1 January to 30 June 2024, Belgium is holding the presidency of the Council of the European Union. The presidency in the area of public health will focus on three major themes: care, preparedness and protection. The FAMHP will use this opportunity to put our priorities on the European agenda and to help define European health policy for the coming years.